Pharma Marketing Network

JUNE 18, 2024

Are you listening to your patient community? We must step forward and be visible, actively engaging in patient communities and embedding the patient voice internally. Show that pharma is driven by more than profit – to build a world that empowers all patients and leaves no one in the dark. It’s not enough.

Pharma 52

Pharma Patients Networking Healthcare 52

PM360

DECEMBER 20, 2024

Courier Health Powered by machine learning AI, Avalere Courier Health was founded in 2021 with the goal of revolutionizing the biopharma landscape with its groundbreaking patient-focused customer relationship management (CRM) platform. In July 2024, Courier Health secured $16.5 It simplifies complex workflows (e.g.,

Customer Relationship Management 52

Customer Relationship Management CRM Biopharma Relationship management 52

European Pharmaceutical Review

JUNE 13, 2024

Tell us about Ocugen’s lead programme, OCU400. In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa. In May 2024, Ocugen announced the second cohort (medium dose) completed dosing in the dose-escalation phase.

Manufacturing 145

Manufacturing Food and Drug Administration Engineering Safety 145

European Pharmaceutical Review

MAY 27, 2024

Repurposing cyclophosphamide may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, new research suggests. The study is assessing patients treated with cyclophosphamide and peripheral blood stem cell (PBSC) transplantation.

Side effects 111

Side effects Leads Patients Pharmaceutical 111

Legacy MEDSearch

DECEMBER 19, 2022

Chairman, Dave Ferrera, announced treatment of the first patients in North America with the BossStent® device designed to treat patients with symptomatic cerebral venous diseases. Both the EU and FDA clinical trials will be initiated in Q2 2023 for the purpose of obtaining European and US regulatory approvals respectively in Q1 2024.

Patients 98

Patients Recruitment Physicians Management 98

Pharma Marketing Network

DECEMBER 6, 2023

The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients.  Delivering aligned value to HCPs, patients, payers and regulators.  We must adapt to evolving payer needs, empower HCPs with crucial insights, bridge regulatory gaps and co-create with patients.

Pharma 52

Pharma Networking Marketing Medicine 52

European Pharmaceutical Review

JUNE 10, 2024

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market. billion.

Manufacturing 98

Manufacturing Distribution Pharmaceutical manufacturing Leads 98

European Pharmaceutical Review

NOVEMBER 21, 2023

Phase III trials of a low carbon version of GSK’s metered dose inhaler, Ventolin (salbutamol), using a next generation, lower carbon propellant, are set to start in 2024. According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler.

Manufacturing 116

Manufacturing Patients Pharma Leads 116

PM360

DECEMBER 20, 2024

After nearly five years of mounting pressures on the American healthcare system, providers and patients are confronting another challenge that shows no signs of slowing down: skyrocketing medical costs. Patients with low incomes are especially vulnerable.

Patients 52

Patients Prescription Retail Insurance 52

PM360

OCTOBER 31, 2024

[Cedar Knolls, 10/29/2024] — A recent study conducted by PURE , the industry’s premier benchmark for evaluating patient support programs (PSPs), has named the best-in-class PSPs across key therapeutic areas. Kulstad commented: “These results provide an insightful roadmap for the future of patient support programs.

Patients 52

Patients Education Consulting Healthcare 52

European Pharmaceutical Review

APRIL 17, 2024

Roche’s twice-yearly, 10-minute subcutaneous injection of OCREVUS ® (ocrelizumab) has shown significant promise for patients with either with relapsing or primary progressive multiple sclerosis (RMS or PPMS). percent had no relapse) in patients through 48 weeks of the treatment. No new safety signals were identified for OCREVUS SC.

Food and Drug Administration 93

Food and Drug Administration Safety Medicine Food 93

LEVO Health

DECEMBER 28, 2023

As we look toward 2024, video marketing is set to become a critical component of a comprehensive marketing strategy. This approach tailors the viewing experience to individual patients, considering their unique needs, preferences, and behaviors. As we look ahead to 2024, AI and machine learning are poised to play an even larger role.

Marketing 52

Marketing Healthcare Healthcare Education 52

European Pharmaceutical Review

JANUARY 5, 2024

“ Treatment with evenamide as an add-on to antipsychotics in treatment-resistant schizophrenia (TRS) patients has produced benefits that have never been reported before,” Ravi Anand, Newron’s Chief Medical Officer shared. This is compared to daily dosing, therefore helping to reduce the peak to trough variation patients can experience.

Food and Drug Administration 111

Food and Drug Administration Medical Safety Patients 111

Pharmaceutical Technology

JUNE 6, 2023

Findings from a two-year placebo-controlled, double-blind Phase II trial showed that Stargardt patients treated with gildeuretinol once a day as a pill experienced a statistically and clinically meaningful slowing of retinal damage over placebo. Alkeus Pharmaceuticals intends to submit a new drug application for gildeuretinol in 2024.

Food and Drug Administration 111

Food and Drug Administration Food Pharmaceutical Medicine 111

European Pharmaceutical Review

APRIL 2, 2024

Wienand will join the contract development and manufacturing organisation (CDMO) in the summer of 2024. Together, we will enable a healthier world for patients in need”. Wolfgang Wienand has been chosen to succeed Albert Baehny as the CEO of Lonza. He has been CEO of the Swiss CDMO Siegfried Holding AG since 2019. billion.

Biopharma 98

Biopharma Leads Manufacturing Pharmaceutical 98

European Pharmaceutical Review

FEBRUARY 14, 2024

Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). percent for patients on seladelpar versus 20.0 percent for patients on seladelpar versus 0.0 Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3

Transportation 97

Transportation Patients Pharma Leads 97

PM360

SEPTEMBER 30, 2024

In this issue, we take a closer look at the patient experience and how it is constantly evolving in the pharma industry. From conducting an easier process of scheduling doctors appointments to how patient feedback plays an important role in enhancing the experience, here is what our specialists had to say. It’s the wrong start-point.

Patients 59

Patients Education Doctors Pharmaceutical 59

European Pharmaceutical Review

MARCH 5, 2024

The company highlighted that 35 percent of patients enrolled in its clinical trials are based in Europe. The company stated that de la Rocha transitioned to the role of Head of Clinical Operations, Europe, in early 2024. BeiGene has appointed Pilar de la Rocha as its new Head of Europe, Global Clinical Operations.

Medicine 98

Medicine Leads Medical Manufacturing 98

European Pharmaceutical Review

DECEMBER 22, 2023

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024. per share in cash.

Food and Drug Administration 98

Food and Drug Administration Side effects Safety Food 98

European Pharmaceutical Review

OCTOBER 28, 2024

Biologic with rapid onset of action Week 12 results showed that over fifty percent of patients treated with subcutaneous TREMFYA at Weeks 0, 4, and 8 obtained clinical remission over placebo, at 21.4 These Phase III results were presented at the American College of Gastroenterology (ACG) 2024 conference. percent, respectively.

Medicine 59

Medicine Patients Management Leads 59

European Pharmaceutical Review

JANUARY 18, 2024

Cell and Gene Therapy Catapult opens new laboratories Leading Europe’s cell and gene therapy sector According to a new report from the UK BioIndustry Association (BIA) in collaboration with Citeline, the UK is making significant moves to affirm its leading position within the cell and gene therapy (CGT) sector.

Distribution 111

Distribution Manufacturing Medicine Government 111

Nixon Gwilt Law

NOVEMBER 30, 2023

Reimbursement for Community Health Integration, Social Determinants Risk Assessment, and Principal Illness Navigation On November 2, the Centers for Medicare and Medicaid Services (“CMS”) released the 2024 Medicare Physician Fee Schedule (“2024 MPFS”) final rule.

Physicians 52

Physicians Patients Training Management 52

Nixon Gwilt Law

NOVEMBER 30, 2023

Reimbursement for Community Health Integration, Social Determinants Risk Assessment, and Principal Illness Navigation On November 2, the Centers for Medicare and Medicaid Services (“CMS”) released the 2024 Medicare Physician Fee Schedule (“2024 MPFS”) final rule.

Physicians 52

Physicians Patients Management Training 52

European Pharmaceutical Review

DECEMBER 5, 2023

Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes. The closing of the transaction is currently expected to occur in the first quarter of 2024.

Food 110

Food Leads Pharma Patients 110

European Pharmaceutical Review

MARCH 18, 2024

A Phase III trial has shown that compared oral drug delivery, administering levodopa through an infusion pump led to nearly two hours of day (1.72) of additional time in which the medicine reduced symptoms in Parkinson’s patients. There were 381 Parkinson’s patients enrolled in the trial. and Joan A.

Food and Drug Administration 98

Food and Drug Administration Medicine Physicians Food 98

PM360

FEBRUARY 23, 2024

The team worked directly with the MG patient community to build a clean story, then the team embraced an educational yet youthful film style.

Education 52

Education Pharma Leads Marketing 52

Penrod

MARCH 7, 2024

Digital patient forms offer a superior solution for the healthcare sector, swiftly supplanting traditional paperwork. The level of detail needed makes the task tedious for most patients. Effective communication is vital when it comes to providing the best patient care. Safeguarding patient data is crucial.

Healthcare 52

Healthcare Healthcare Patients Leads 52

pharmaphorum

SEPTEMBER 6, 2022

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to regulatory filings in the US and EU. The Series A round includes €3.6

Leads 103

Leads Biopharma Government Patients 103

Nixon Gwilt Law

MAY 17, 2024

ATA Nexus 2024: 4 Game-Changing Takeaways for Healthcare Innovators The ATA Nexus 2024 Conference , one of the largest gatherings of virtual healthcare experts and thought leaders, just took place in Phoenix last week. Integrating your data – Healthcare workers are receiving large quantities of data from patients around the clock.

Healthcare 52

Healthcare Healthcare Patients Training 52

European Pharmaceutical Review

MAY 21, 2024

Initial data from a Phase III maintenance study of TREMFYA ® (guselkumab) has demonstrated promising remission rates obtained from a dual-acting monoclonal antibody given to ulcerative colitis (UC) patients. This data from Johnson & Johnson’s Phase III QUASAR study is being presented at Digestive Disease Week 2024 (Abstract #759).

Patients 105

Patients Leads Pharmaceutical 105

European Pharmaceutical Review

JUNE 5, 2024

These findings from GSK reflect outcomes from 42 patients with mismatch repair deficient (dMMR) locally advanced rectal cancer who finished the treatment. GSK highlighted that the first 24 patients demonstrated “a sustained clinical complete response, with a median follow-up of 26.3 months was observed”.

Safety 98

Safety Patients Manufacturing Medicine 98

European Pharmaceutical Review

NOVEMBER 27, 2023

The study will provide “meaningful and robust results on the efficacy and tolerability” of its lead drug candidate BC 007 in individuals with Long COVID. Studies evaluated individuals who were healthy and fAAB-positive in a Phase I study and in heart failure patients in a Phase IIa trial.

Recruitment 130

Recruitment Leads Pharmaceutical Patients 130

European Pharmaceutical Review

NOVEMBER 28, 2023

According to the FDA, this clinical trial evaluated 142 adult patients with progressing desmoid tumours not suitable to surgery. Patients were randomised to receive 150mg of Ogsiveo or placebo. A response rate of 41 percent was observed in the Ogsiveo arm, while this rate was eight percent in the placebo arm.

Food and Drug Administration 104

Food and Drug Administration Medicine FDA Food 104

Nixon Gwilt Law

MAY 17, 2024

ATA Nexus 2024: 4 Game-Changing Takeaways for Healthcare Innovators The ATA Nexus 2024 Conference , one of the largest gatherings of virtual healthcare experts and thought leaders, just took place in Phoenix last week. Integrating your data – Healthcare workers are receiving large quantities of data from patients around the clock.

Healthcare 52

Healthcare Healthcare Training Healthcare Provider 52

PM360

JUNE 23, 2023

Press Release Contact: Kayla Walsh Awards Coordinator, PM360 646-300-8114 kayla.walsh@pm360online.com PM360 Now Accepting Entries for 2024 Pharma Choice Awards Call for the Best Healthcare Creative from the Past Year NEW YORK, NY, June 22, 2023 : The 2024 PM360 Pharma Choice Awards are officially open for entries.

Pharma 52

Pharma Marketing Healthcare Healthcare 52

PM360

DECEMBER 20, 2024

Volta Medical One in four adults over 40 years old are at risk for developing atrial fibrillation (AF), a condition that can lead to blood clots, stroke, heart failures, and other heart-related complications. Despite this, AF often goes mismanaged, especially in its early stages, leaving patients vulnerable to severe health risks.

Medical 52

Medical Healthcare Healthcare Leads 52

Eversana Intouch

SEPTEMBER 27, 2024

With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. And I am on site at ESMO 2024 in sunny Barcelona. EVERSANA was there with teams from across the U.S.

Patients 59

Patients Medical Healthcare Healthcare 59